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OBJECTIVES: Contrast-induced adverse drug reactions (ADRs),
including contrast-induced nephropathy (renal insufﬁciency and
diabetes), are common among high-risk patients (e.g., patients
with diabetes mellitus and renal impairment). These ADRs cause
extended hospital stays and additional medication use which lead
to increased costs. We examine the cost-effectiveness of the use of
2 contrast media in patients at high risk for contrast-induced
nephropathy. METHODS: A decision-analytic model was con-
structed to estimate the cost-effectiveness of an isosmolar con-
trast agent, iodixanol, compared to a low-osmolar contrast
medium, iohexol, in the UK. Particular emphasis of the model
was to avert the incidence of severe ADRs in patients at
risk of contrast-induced nephropathy. The analysis is based
on a European multi-centre randomised controlled trial, the
NEPHRIC trial, of patients receiving iodixanol versus ohexol in
which a statistically signiﬁcant reduction in the incidence of
severe ADRs in favour of iodixanol occurred. Patients in the
study were adults 18 years of age or older referred for coronary
or aortofemoral angiography, had diabetes and stable serum
creatinine concentrations (men: 1.5 to 3.5 mg/dL; women: 1.3 to
3.5 mg/dL). ADRs considered included acute renal failure,
arrhythmia, cardiovascular events, pulmonary edema, and
multiple-organ failure. Resource use, including hospital days,
medical visits, contrast medium, medications, laboratory tests
and hospital procedures, were obtained from the NEPHRIC
clinical trial. Unit costs data were obtained from standard UK
costing sources. Costs are reported in 2006 £s. RESULTS: Iodix-
anol is cost-effective compared to iohexol with both lower costs
and better effects related to fewer ADRs. The mean per patient
cost difference was 555.98 (0.41 and 556.39for iodixanol
and iohexol, respectively). CONCLUSION: Iodixanol results in
fewer ADRs and lower ADR costs per patient for this high risk
patient population.
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OBJECTIVES: Cardiovascular (CV) risk and diseases represent
signiﬁcant public health problem in Hungary. Rimonabant is
the ﬁrst in a new class of drugs called CB1-receptor-antagonists
that improves multiple cardiometabolic risk factors such as
waist circumference, HbA1c, HDL and TG in overweight/
obese patients. The objective of our study is to assess the cost-
effectiveness of rimonabant in the management of obese, or
overweight patients with cardiometabolic risk factors, such as
type 2 diabetes or dyslipidemia, in Hungary. METHODS: A
Markov model was developed to assess the cost-effectiveness of
rimonabant. Clinical outcomes were derived from RIO-Diabetes
study and published equations were used to calculate the cardio-
vascular risks associated with obesity, and to determine the devel-
opment of diabetes. Utilities applied in the model were primarily
derived from the HODaR database. Hungarian direct costs at
2005 price level were calculated from database and question-
naires, using patient level resource use and cost data. The analy-
sis was performed from the payer’s perspective. The costs and
outcomes were discounted at 5%/year. Deterministic and proba-
bilistic sensitivity analyses were performed. RESULTS: Adding
rimonabant to diet and exercise for 1 year is estimated to gain 56
QALYs for 1000 patients over lifetime. The savings resulting
from CV events avoided could partly offset the cost of rimona-
bant, resulting incremental cost of €688 (169,132 HUF) per
patient. One QALY costs €12,226 (3,004,735 HUF). Cost/QALY
ratio after using RIO-Lipids in sensitivity analysis still remained
acceptable in Hungary. CONCLUSION: Rimonabant, added to
diet and exercise, can represent a cost-effective therapy compared
to diet and exercise alone in the treatment of obese, or over-
weight patients with associated risk factor(s), such as type 2
diabetes or dyslipidaemia in Hungary.
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OBJECTIVES: Although the primary endpoint in the IDEAL
study did not fully reach signiﬁcance, the study showed that
treatment with 80 mg atorvastatin daily led to a signiﬁcant
reduction in non-fatal myocardial infarction (MI) and revascu-
larizations compared to 20–40 mg simvastatin. A separate
analysis of patients with acute coronary syndromes showed a
relative reduction of the risk of MI of 46%. Here we investi-
gate the economic impact of this in Sweden. METHODS: A
Markov model was constructed deriving transition probabilities
from the intention-to-treat patient-level data in IDEAL. The
model incorporated states for MI and revascularizations.
Patients are treated for the duration of the trial (5 years), and
followed for the remainder of their lives. Resource consump-
tion associated with events was estimated based on the trial
data. Analyses were conducted from a societal perspective with
costs expressed in year 2007€. Effectiveness was measured as
quality adjusted life years (QALY) gained. Costs and effects
were discounted at 3% per annum. Uncertainty was assessed
through one-way sensitivity analysis and 2nd order Monte
Carlo analysis where all parameter inputs were drawn from
their underlying distributions. RESULTS: The predicted quality-
adjusted survival of 10.65 years in the atorvastatin arm com-
pared to 10.52 years in the simvastatin arm, an increase of 0.13
QALYs. Total life-time costs in the atorvastatin arm were
9387€ compared to 8888€, a difference of 499€. The cost to
gain one QALY was 2361€. The results were robust to varia-
tion in model input parameters. CONCLUSION: Compared to
the benchmarks used by the Swedish National Board of Health
and Welfare in their prioritization guidelines in cardiovascular
care, high dose atorvastatin would be cost-effective in the
studied indication. As the present analysis represents a sub-
group analysis of the IDEAL study the results should be inter-
preted with caution.
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